Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium is the major intracellular cation; it maintains intracellular osmolality, cell membrane potential, and normal neuromuscular excitability. Dextrose provides caloric support; sodium chloride maintains extracellular fluid osmolality.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
40 mEq potassium chloride intravenously, infused at a rate not exceeding 10 mEq/hour, typically once daily or as needed to correct hypokalemia.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life approximately 24 hours; reflects redistribution from intracellular to extracellular compartments; prolonged in renal impairment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% excreted unchanged in urine; minimal fecal or biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte